Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
Second Sight's Argus II Retinal Prosthesis System selected for Forfait Innovation reimbursement

Second Sight's Argus II Retinal Prosthesis System selected for Forfait Innovation reimbursement

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Newly developed compound may allow blind see light

Newly developed compound may allow blind see light

Clinician scientist receives RPB Career Development Award to support eye research

Clinician scientist receives RPB Career Development Award to support eye research

New gene therapy restores some sight in people born with inherited form of blindness

New gene therapy restores some sight in people born with inherited form of blindness

Optogenetics offers a promising therapy for retinal degeneration

Optogenetics offers a promising therapy for retinal degeneration

Study: New device helps people who lost vision due to blinding genetic disease

Study: New device helps people who lost vision due to blinding genetic disease

Key marker in blood and urine identifies genetic mutations in gene responsible for RP

Key marker in blood and urine identifies genetic mutations in gene responsible for RP

Barcelona to host European Drosophila Research Conference

Barcelona to host European Drosophila Research Conference

Researchers make breakthrough discovery in diagnosing retinitis pigmentosa

Researchers make breakthrough discovery in diagnosing retinitis pigmentosa

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Research holds promise for developing treatments for retinitis pigmentos

Research holds promise for developing treatments for retinitis pigmentos

Researchers identify mutation in CNGB1 gene causing PRA in Phalene and Papillon

Researchers identify mutation in CNGB1 gene causing PRA in Phalene and Papillon

Research findings offer clues to the origin of retinal disorders later in life

Research findings offer clues to the origin of retinal disorders later in life

Vanderbilt offers first FDA-approved bionic eye for treatment of retinitis pigmentosa

Vanderbilt offers first FDA-approved bionic eye for treatment of retinitis pigmentosa

University of Florida receives RPB Sanders Construction grant

University of Florida receives RPB Sanders Construction grant

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.